Spyglass Pharma

What Spyglass Pharma does

SpyGlass Pharma, Inc. is a late-stage, publicly traded biopharmaceutical company (Nasdaq: SGP) headquartered in Aliso Viejo, California, developing sustained drug-delivery systems for chronic ophthalmic diseases. Founded in 2019 by Malik Y. Kahook, MD, and Glenn Sussman as a spin-off from the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine, the company's lead product is the BIM-IOL System, an intraocular lens implant that integrates two non-bioerodible bimatoprost-eluting drug pads at the optic-haptic junction to deliver glaucoma medication directly into the aqueous humor for up to three years during routine cataract surgery. In clinical trials, the system demonstrated a 37% mean reduction in intraocular pressure sustained through 36 months and enabled 95% of evaluable patients to discontinue topical IOP-lowering medications. The pipeline also includes the BIM-DRS (Drug Ring System), a next-generation removable and replaceable implant designed for multi-year bimatoprost delivery as both a standalone procedure and a re-treatment option for prior BIM-IOL recipients.

The company is currently advancing the BIM-IOL System through two registrational Phase 3 trials (SGP-005 and SGP-006) initiated in July 2025, targeting a potential FDA approval and U.S. commercial launch in 2029. The BIM-IOL System is designed for use by general cataract surgeons without specialized MIGS training, addressing a market where only 33% of cataract surgeons routinely perform glaucoma procedures and where approximately 1 million U.S. glaucoma/OHT patients undergo cataract surgery annually against a Stifel-estimated $13 billion U.S. addressable opportunity. A dedicated CPT Category III add-on code (X659T) has been secured to establish a reimbursement pathway for surgeons.

The business model centers on direct sale of the prescription medical device to hospitals and ambulatory surgical centers, with a VP of Commercial and VP of Marketing recently hired to build the U.S. commercial organization. The company has raised approximately $325 million cumulatively, including a $90 million Series C (2023, led by RA Capital), a $75 million Series D (2025, led by Sands Capital), and a $150 million IPO on Nasdaq in February 2026. As of late 2025, SpyGlass Pharma remained pre-revenue with a $27.3 million net loss for the nine months ending September 30, 2025 and $106 million in cash, reflecting pure clinical-stage burn ahead of the planned 2029 launch.

Name

Spyglass Pharma

Legal name

SpyGlass Pharma, Inc.

Website

https://spyglasspharma.com

Company type

Public

Founded year

2019

Operating status

Ipo

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Sustained-release ophthalmic implants
• Drug-eluting intraocular lenses
• Glaucoma treatment devices
• Cataract surgery therapeutics
• Ocular drug delivery systems

Headquarters

HQ city

Aliso Viejo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Product Sales: Once approved, the company plans to commercialize the BIM-IOL System through direct sales to hospitals, ambulatory surgical centers, and ophthalmologists performing cataract surgery. Revenue will be generated from the sale of the drug-delivering intraocular lens system. The company is preparing for commercial launch with key leadership hires in marketing and commercial operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Spyglass Pharma develops and plans to commercialize the BIM-IOL System, a drug-eluting intraocular lens implant that delivers bimatoprost for up to three years during routine cataract surgery. The product targets patients with primary open-angle glaucoma or ocular hypertension who are undergoing cataract surgery, combining vision correction with sustained intraocular pressure reduction in a single procedure. The company is also developing the next-generation BIM-DRS (Drug Ring System) as a standalone supraciliary drug delivery platform.

Product overview

SpyGlass Pharma is a late-stage biopharmaceutical company developing sustained drug delivery systems for chronic eye conditions. The company offers two main products: the BIM-IOL System, an intraocular lens implant that delivers glaucoma medication (bimatoprost) continuously for up to 3 years during routine cataract surgery, and the BIM-DRS (Drug Ring System), a next-generation removable and replaceable implant for multi-year drug delivery that serves as a re-treatment option. Both products are designed to address the treatment gap for glaucoma patients who struggle with daily eye drop adherence.

Differentiator

Problem solved

Functional benefit

Products and services

• BIM-IOL System

Quantifiable outcome

• 37% mean IOP reduction sustained over 36 months in first-in-human trial
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• University of Colorado Anschutz School of MedicinecoreStrategic or Co-development PartnerSpyGlass Pharma was spun off from CU Anschutz in 2019, originating from the Sue Anschutz-Rodgers Eye Center. The company was founded by Malik Y. Kahook, MD, a leading ophthalmic surgeon and academic from the institution.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Glaukos Corporation: Direct competitor developing sustained-release ocular drug delivery for glaucoma, including the iDose TR (travoprost-eluting intracameral implant) approved in 2023. Targets the same MIGS-adjacent surgeon call point and glaucoma patient population as SpyGlass.
• EyePoint Pharmaceuticals: Closest direct competitor with DURYSTA, a bioerodible bimatoprost-eluting intracameral implant for glaucoma. Uses the same active pharmaceutical ingredient as SpyGlass's BIM-IOL, validating the bimatoprost sustained-release thesis while highlighting adoption challenges.
• Ocular Therapeutix: Sustained-release ophthalmic drug delivery company with DEXTENZA (intracanalicular dexamethasone insert) and pipeline programs targeting glaucoma and other chronic eye diseases. Shares SpyGlass's drug-eluting implant business model and ophthalmic specialty focus.
• Sight Sciences: Ophthalmic medical device company focused on MIGS solutions (OMNI Surgical System) for glaucoma. Targets the same cataract surgeon channel and addresses the same patient population of glaucoma patients undergoing cataract surgery.

Broad incumbents

• Alcon: Global leader in cataract surgery (IOLs, surgical equipment) and glaucoma (iStent MIGS portfolio). Competes directly with SpyGlass across the cataract surgery workflow and has the surgeon relationships and commercial scale to bundle competing solutions.
• Bausch + Lomb: Major diversified ophthalmic company with a leading IOL portfolio and surgical glaucoma offerings. Would compete with SpyGlass across the cataract surgery suite and has deep relationships with U.S. ophthalmic surgeons.
• AbbVie (Allergan Aesthetics / Eye Care): Owns the Lumigan (bimatoprost) franchise that SpyGlass's BIM-IOL is designed to replace, creating both a competitive threat and validation of the bimatoprost opportunity. Allergan's eye care business also markets DURYSTA via collaboration.

Emerging players

• iStar Medical: European-based MIGS developer with MINIject supraciliary implant for glaucoma. Targets overlapping patient populations and surgeon call points, though its technology is structural rather than drug-delivery-based.
• Aerie Pharmaceuticals (Alcon subsidiary): Develops novel glaucoma therapies including Rocklatan and Rhopressa; now part of Alcon. Represents the topical glaucoma therapy paradigm SpyGlass seeks to displace, and the acquisition by Alcon highlights strategic value of differentiated glaucoma assets.

Regional players

• Santen Pharmaceutical: Japan-headquartered specialty ophthalmic pharmaceutical company with a strong glaucoma franchise (tapcom/tafluprost, DE-117A) and growing U.S. presence. Represents a potential ex-U.S. partner or acquirer with established glaucoma commercial infrastructure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/spyglasspharma
• Xx.com/SpyGlassPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spyglass Pharma